First time intravesically administered trifunctional antibody catumaxomab in patients with recurrent non-muscle invasive bladder cancer indicates high tolerability and local immunological activity
Authors (first, second and last of 5)

Since its inception in 1976, Cancer Immunology, Immunotherapy (CII) has reported significant advances in the field of tumor immunology. The journal serves as a forum for new concepts and advances in basic, translational, and clinical cancer immunology and immunotherapy. CII is keen to publish broad-ranging ideas and reviews, results which extend or challenge established paradigms, as well as negative studies which fail to reproduce experiments that support current paradigms, and papers that do succeed in reproducing others’ results in different contexts. Cll is especially interested in papers describing clinical trial designs and outcome regardless of whether they met their designated endpoints or not, and particularly those shedding light on immunological mechanisms.
CII is affiliated with the Association for Cancer Immunotherapy (CIMT), Canadian Cancer Immunotherapy Consortium (CCIC), The Japanese Association for Cancer Immunology (JACI), Network Italiano per la Bioterapia dei Tumori (NIBIT), and Sociedad Española de Inmunologia-Grupo Española de InmunoTerapia (SEI-GEIT).
CIMT: http://www.cimt.eu/home
CCIC: http://www.immunotherapycancer.ca/
JACI: http://www.jaci.jp/eng/index.html
NIBIT: http://www.nibit.org/index.php
SEI-GEIT: http://www.inmunologia.org/grupos/home.php?UpOm5=M&Upfqym5uom=GK
CITIM: http://www.canceritim.org 94% of authors who answered a survey reported that they would definitely publish or probably publish in the journal againAs a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times. Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.
The journal is pleased to announce Dr. Haidong Dong has been named the new Editor-in-Chief of Cancer Immunology, Immunotherapy, effective January 1, 2020.